S&P 500

5.221,56

-0,02%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

0RU5

Bergenbio Asa (0RU5)

Bergenbio Asa

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:LSE:0RU5

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
22/08/2023	05:50	PR Newswire (US)	BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer	LSE:0RU5	Bergenbio Asa
26/05/2023	10:07	PR Newswire (US)	BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue	LSE:0RU5	Bergenbio Asa
25/04/2023	13:26	PR Newswire (US)	BerGenBio ASA: Proposed partially underwritten rights issue	LSE:0RU5	Bergenbio Asa
18/04/2023	02:23	PR Newswire (US)	BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR	LSE:0RU5	Bergenbio Asa
09/03/2023	07:22	PR Newswire (US)	BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations	LSE:0RU5	Bergenbio Asa
16/02/2023	03:32	PR Newswire (US)	BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update	LSE:0RU5	Bergenbio Asa
15/02/2023	13:35	PR Newswire (US)	BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	LSE:0RU5	Bergenbio Asa
02/02/2023	03:17	PR Newswire (US)	BerGenBio Announces the Establishment of Oncology Scientific Advisory Board	LSE:0RU5	Bergenbio Asa
15/11/2022	03:10	PR Newswire (US)	BerGenBio reports third quarter 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
25/10/2022	02:37	PR Newswire (US)	BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS	LSE:0RU5	Bergenbio Asa
11/10/2022	02:36	PR Newswire (US)	BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	LSE:0RU5	Bergenbio Asa
27/09/2022	10:31	PR Newswire (US)	BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS	LSE:0RU5	Bergenbio Asa
23/08/2022	02:36	PR Newswire (US)	BerGenBio reports second quarter and half year 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
04/05/2022	02:29	PR Newswire (US)	BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19	LSE:0RU5	Bergenbio Asa
26/04/2022	02:13	PR Newswire (US)	BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET	LSE:0RU5	Bergenbio Asa
11/04/2022	02:12	PR Newswire (US)	BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer	LSE:0RU5	Bergenbio Asa
07/04/2022	09:20	PR Newswire (US)	BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021	LSE:0RU5	Bergenbio Asa
16/02/2022	03:09	PR Newswire (US)	BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021	LSE:0RU5	Bergenbio Asa
27/01/2022	03:21	PR Newswire (US)	BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients	LSE:0RU5	Bergenbio Asa
09/11/2021	10:19	PR Newswire (US)	BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced/Metastatic Non-small Lung Cancer (NSCLC)	LSE:0RU5	Bergenbio Asa
09/11/2021	10:18	PR Newswire (US)	Bergenbio Presents Pre-clinical and Clinical Data on Bemcentinib in STK11-positive NSCLC at SITC Annual Meeting 2021	LSE:0RU5	Bergenbio Asa
12/07/2021	09:31	PR Newswire (US)	BerGenBio Presents Encouraging Combined Data for Bemcentinib from Two Phase II COVID-19 Studies at ECCMID	LSE:0RU5	Bergenbio Asa
11/06/2021	04:38	PR Newswire (US)	Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting	LSE:0RU5	Bergenbio Asa
18/05/2021	02:21	PR Newswire (US)	BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients	LSE:0RU5	Bergenbio Asa
19/04/2021	02:26	PR Newswire (US)	BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients	LSE:0RU5	Bergenbio Asa
06/03/2021	10:59	PR Newswire (US)	BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021)	LSE:0RU5	Bergenbio Asa
04/03/2021	03:22	PR Newswire (US)	Bergenbio Closes Recruitment Into Trial Assessing Bemcentinib In Covid-19 Patients	LSE:0RU5	Bergenbio Asa
17/02/2021	03:20	PR Newswire (US)	BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021)	LSE:0RU5	Bergenbio Asa
06/12/2020	16:23	PR Newswire (US)	BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020	LSE:0RU5	Bergenbio Asa
11/11/2020	10:21	PR Newswire (US)	BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting	LSE:0RU5	Bergenbio Asa